A Study to Evaluate the Safety and Efficacy of Ruxolitinib Cream in Pediatric Participants With Nonsegmental Vitiligo
← catalyst calendarSponsored by Incyte Corporation (industry) · INCY — their whole pipeline →.
Phase
Phase 3
Status
Recruiting
Study type
Interventional
Design
Randomized · Triple · Treatment
Enrollment
180estimated
Sites
98
Countries
Canada, United States
Every value on this page is a field the sponsor filed with ClinicalTrials.gov, reproduced. Dates are their own estimates, revised as a study runs, unless the registry marks them actual. sources →
Source: ClinicalTrials.gov, retrieved 2026-08-19
Dates
each axis at the precision it was filed, with the registry's own basis| Date | Filed | Basis | What it is |
|---|---|---|---|
| Start | 2025-01-24 | actual | When the study began enrolling |
| Primary completion | 2026-08-10 | estimated | The date the last participant is measured for the primary outcome — the readout window |
| Study completion | 2027-03-13 | estimated | The whole study's end, after follow-up |
| First posted | 2024-08-12 | actual | When this record first appeared on the registry |
| Results posted | — | When the sponsor posted results to the registry | |
| Record updated | 2026-07-23 | actual | The sponsor's own last edit to this record — every projection above is as current as this date |
What it studies
Condition
- NonSegmental Vitiligo
Interventions
- Drug: Ruxolitinib Cream — also filed as INCB018424 Phosphate Cream
- Drug: Vehicle Cream
Primary outcome
what the primary-completion date above is the date OFProportion of Participants Achieving a ≥ 75% Improvement From Baseline in the Facial Vitiligo Area Scoring Index (F-VASI75)
measured Week 24
Permalink · INCY's whole pipeline · Catalyst calendar · Every registered study · What changed